Minute Insight: Pear Therapeutics Files For Bankruptcy, Hopes To Find Buyer For PDT Assets

A few weeks after announcing that it was exploring its "strategic options," Pear Therapeutics announced that it is filing for bankruptcy and is not filling new prescriptions for its digital therapeutics.

Minute Insight
• Source: Informa/Alamy

Pear Therapeuticsfiled for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware and intends to pursue a sale of the business or its assets.

“We also announced a reduction in force, including me,” Pear founder and now-former-CEO Corey McCann posted on social media on 7 April. “This is certainly not the outcome I...

Pear Therapeutics marketed the reSET and reSET-O prescription cognitive behavioral therapy-based digital therapeutics (PDTs) for drug and opioid addiction as well as the Somryst digital therapeutic to treat insomnia via...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.